research article review on bevacizumab production

 Bevacizumab is a recombinant humanized monoclonal antibody that targets the vascular endothelial growth factor (VEGF) protein. It is used to treat a variety of cancers, such as colorectal, lung, glioblastoma, and renal cell carcinomas. Bevacizumab was first approved by the US Food and Drug Administration (FDA) in 2004 for the treatment of metastatic colon and lung cancer.

The development of bevacizumab began in the late 1990s, when scientists at Genentech, a subsidiary of Roche, recognized the potential of targeting VEGF for the treatment of cancer. The VEGF protein is known to promote the growth of new blood vessels, which is essential for the growth and spread of tumors. By targeting VEGF, bevacizumab can inhibit the growth of new blood vessels and thus, slow the growth of tumors.

To develop bevacizumab, Genentech scientists first identified a mouse monoclonal antibody that binds to VEGF, and then humanized it to minimize the potential for an immune response. The humanized antibody was then expressed in Chinese hamster ovary (CHO) cells using recombinant DNA technology.

The development of bevacizumab also required extensive preclinical and clinical testing to determine its safety and efficacy. In phase I and II clinical trials, bevacizumab was shown to be well-tolerated and to have anti-tumor activity in patients with various types of cancer. In phase III clinical trials, bevacizumab was shown to significantly improve the progression-free survival and overall survival of patients with metastatic colon and lung cancer when given in combination with standard chemotherapy.

In conclusion, the development of bevacizumab required a combination of basic research, protein engineering, recombinant DNA technology, and extensive preclinical and clinical testing. The drug was able to inhibit the growth of new blood vessels and slow the growth of tumors, which made it effective in treating a variety of cancers. Bevacizumab is now widely used as a targeted therapy in oncology, and it has been approved for the treatment of multiple types of cancer.

Comments

Post a Comment

Popular posts from this blog

article review on tocilizumab production

Tocilizumab (Actemra) is a humanized monoclonal antibody that targets the interleukin-6 (IL-6) receptor, which is involved in the inflammatory response. It is used to treat rheumatoid arthritis, systemic juvenile idiopathic arthritis and other inflammatory conditions. It is produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells. One research article "Development of an efficient and scalable fed-batch culture process for the production of tocilizumab in Chinese hamster ovary cells" by Li et al. (2019) aimed to optimize the production of tocilizumab using a fed-batch cultivation system in CHO cells. The study aimed to improve the yield and quality of the protein, and to develop a process that can be easily scaled up for industrial production. The results of the study showed that the yield of tocilizumab was significantly improved by optimizing the culture conditions, such as the temperature, pH, and dissolved oxygen, as well as by using a specific ...
Read more

article review on adalimumab production

Adalimumab is a recombinant human monoclonal antibody that is used to treat a variety of inflammatory diseases, such as rheumatoid arthritis, psoriasis, and Crohn's disease. It is produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells. A research article "Development of a high-titer, high-density fed-batch process for the production of adalimumab in CHO cells" by Chen et al. (2018) aimed to improve the production of adalimumab by developing a high-titer and high-density fed-batch process. The study used a CHO cell line that had been modified to express the adalimumab gene. The cells were grown in a culture medium containing glucose, amino acids, and a proprietary feed supplement, and the culture conditions were optimized to achieve high yields of the protein. The results of the study showed that a high yield of adalimumab (over 2g/L) was achieved using the fed-batch cultivation system. The study also found that the specific productivity of th...
Read more

effect of ph on rituximab production

The pH of the culture medium is an important parameter that affects the growth and productivity of cells in a bioreactor. The pH can affect the solubility, stability and activity of enzymes, as well as the uptake and metabolism of nutrients. In the case of rituximab production, the pH can affect the stability and activity of the protein, as well as the productivity of the cells. Optimal pH for rituximab production in Chinese hamster ovary (CHO) cells usually ranges from 7.0 to 7.5. A pH that is too low or too high can cause the protein to denature or aggregate, reducing its activity and stability. Additionally, a pH that is too low or too high can also cause stress to the cells, reducing their productivity. A research article "Development of a high-titer, high-density fed-batch process for the production of Rituximab in Chinese Hamster Ovary (CHO) cells" by Wang et al. (2015) aimed to improve the production of rituximab by developing a high-titer and high-density fed-batc...
Read more